CYTK LAWSUIT ALERT: Levi & Korsinsky Notifies Cytokinetics, Incorporated Investors - Lead Plaintiff Deadline November 17, 2025

New York, New York--(Newsfile Corp. - November 17, 2025) - If you suffered a loss on your Cytokinetics, Incorporated (NASDAQ: CYTK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:

https://zlk.com/pslra-1/cytokinetics-incorporated-lawsuit-submission-f ...

or contact Joseph E. Levi, Esq. via email at [e-mail] or call [phone] to speak to our team of experienced shareholder advocates.

THE LAWSUIT: A class action securities lawsuit was filed against Cytokinetics, Incorporated that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between December 27, 2023 and May 6, 2025.

CASE DETAILS: According to the complaint, defendants made materially false and misleading statements regarding the timeline for the New Drug Application ("NDA") submission and approval process for aficamten. Specifically, defendants represented that the Company expected approval from the U.S. Food and Drug Administration ("FDA") for its NDA for aficamten in the second half of 2025, based on a September 26, 2025 PDUFA date, and failed to disclose material risks related to the Company's failure to submit a Risk Evaluation and Mitigation Strategy ("REMS") that could delay the regulatory process.

On May 6, 2025, during an earnings call, it was revealed that the Company had multiple pre-NDA meetings with the FDA discussing safety monitoring and risk mitigation but chose to submit the NDA without a REMS, relying on labeling and voluntary education materials. This confirmed defendants' awareness of potential REMS requirements and their reckless decision to omit it from the initial submission, misleading investors about the regulatory timeline.

As a result of defendants' false and misleading statements, class members purchased Cytokinetics' common stock at artificially inflated prices and suffered significant losses when the truth was revealed.

WHAT'S NEXT? If you suffered a loss in Cytokinetics stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/cytokinetics-incorporated-lawsuit-submission-f ... to learn about your rights to seek a recovery. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[e-mail]
Tel: [phone]
Fax: [phone]
https://zlk.com/

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274858

The Cytokinetics Stock at the time of publication of the news with a raise of +0,44 % to 57,50EUR on Lang & Schwarz stock exchange (17. November 2025, 22:00 Uhr).